Cross-Sector entity
Acadia Pharmaceuticals is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. Coverage clusters in earnings, which accounts for 1 of those 3, with the remainder spread across 2 other categories. The tracked stories average 2 original sources each.
3 verified stories tracked
Last mentioned: Feb 27, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Acadia Pharmaceuticals is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. Coverage clusters in earnings, which accounts for 1 of those 3, with the remainder spread across 2 other categories. The tracked stories average 2 original sources each. Daybue appears in 3 tracked Cross-Sector stories from February 27, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Daybue. Shared-story counts are live from our verified record — not editorial picks.
Q4 Earnings Call
ACADIA reports strong year-end results and 2026 guidance.
Daybue Stix Launch
Launch of the granule formulation to enhance patient compliance.
Fiscal Milestone
ACADIA reports record quarterly revenue and achieves annual GAAP profitability.
Trial Setback
Phase 3 ADVANCE-2 trial for pimavanserin in schizophrenia fails to meet primary endpoint.
Commercial Launch
Daybue officially enters the U.S. market with strong initial uptake.
FDA Approval
Daybue (trofinetide) approved as the first treatment for Rett syndrome.
Nuplazid Approval
FDA approves Nuplazid for Parkinson's disease psychosis.
Alkami Technology reported strong Q4 2025 results, highlighting a significant shift toward cloud-native digital banking platforms among regional financial institutions. The company's performance, alongside ACADIA Pharmaceuticals' commercial growth, underscores a resilient market for specialized SaaS and high-margin healthcare solutions.
ACADIA Pharmaceuticals delivered a strong Q4 performance, underscored by the rapid adoption of Daybue and the resilience of its Parkinson’s franchise. The results highlight a successful transition into a diversified commercial-stage biotech with a clear path to sustained profitability.
ACADIA Pharmaceuticals reported a transformative fourth quarter, highlighted by the rapid commercial expansion of Daybue for Rett syndrome and the steady performance of Nuplazid. The company has successfully achieved GAAP profitability, signaling a robust shift toward a diversified rare disease and neurology portfolio.
Source: finance.yahoo.com · finance.yahoo.com
